23 February 2022 NICE will be publishing their, long awaited, report on Oncimmune Holdings (LON:ONC) assessing EarlyCDT Lung https://www.nice.org.uk/guidan...
Am I right in thinking that one of their medical directors stood down last year based on the anticipated, sub-par, findings of this report?
3.12 The committee acknowledged that the evidence to support the use of the EarlyCDT Lung to assess the malignancy risk of solid lung nodules is weak. So, the full benefits and potential harms of widespread use of EarlyCDT Lung testing cannot be reliably quantified. There is no robust data to show the clinical utility of EarlyCDT Lung testing, specifically:
